Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

<h4>Background</h4>Roflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of roflumilast and its active metabolite rof...

Полное описание

Библиографические подробности

Главные авторы:	Amparo Buenestado, Marie-Camille Chaumais, Stanislas Grassin-Delyle, Paul-André Risse, Emmanuel Naline, Elisabeth Longchampt, Hermann Tenor, Philippe Devillier
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Public Library of Science (PLoS) 2013-01-01
Серии:	PLoS ONE
Online-ссылка:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24066150/pdf/?tool=EBI
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!